SCHEMBL12201985

SCHEMBL12201985

COc1cc(C)ccc1S(=O)(=O)Nc1ccc(Cl)cc1C(=O)Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
ALDH1A1 P00352 1/20 0.56
MAPK1 P28482 1/20 0.51
WDR5 P61964 2/20 0.49
METAP2 P50579 1/20 0.49
MEP1B Q16820 1/20 0.48
BRD4 O60885 1/20 0.48
MRGPRX1 Q96LB2 1/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
TP53 P04637 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KCNMA1 Q12791 1/20 0.47
NPC1 O15118 1/20 0.47
TSHR P16473 1/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.47
MAPT P10636 1/20 0.47
ALPL P05186 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12201314 0.91 METAP2 (0.61) KMT2AMEN1ALDH1A1MAPK1WDR5
SCHEMBL12201332 0.88 MEN1 (0.51) KMT2AMEN1ALDH1A1MAPK1MEP1B
SCHEMBL4650453 0.79 ALDH1A1 (0.56) KMT2AMEN1ALDH1A1MAPK1WDR5
SCHEMBL7409071 0.79 LMNA (0.71) KMT2AMETAP2LMNAHTTTP53
SCHEMBL14267581 0.78 KCNA5 (0.49) KMT2AMEN1ALDH1A1LMNAHTT
SCHEMBL12201438 0.78 MEN1 (0.61) KMT2AMEN1ALDH1A1METAP2MEP1B
SCHEMBL492089 0.76 METAP2 (0.80) KMT2AMEN1ALDH1A1METAP2LMNA
SCHEMBL5958896 0.75 FLT1 (0.60) KMT2AMEN1ALDH1A1MEP1BKCNMA1
SCHEMBL491592 0.73 ACLY (0.62) KMT2AMETAP2LMNAHTTTP53
SCHEMBL15354038 0.73 HTT (0.72) KMT2AMEN1METAP2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1385820-B1 ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF SANOFI AVENTIS DEUTSCHLAND (DE) 2011-10-12 EP disclosed
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE KCNH1, KCNH2, KCNJ2 KMT2A 587/4885MEN1 3308/4885ALDH1A1 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.